Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Head titubation17.01.06.0060.000846%Not Available
Suicidal behaviour19.12.01.0060.002538%Not Available
Treatment failure08.06.01.0170.000331%Not Available
Abdominal wall haemorrhage24.07.02.036; 07.16.05.002--Not Available
Skin mass23.07.04.0140.000846%Not Available
Fasting26.01.02.001--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.001692%
Reversible cerebral vasoconstriction syndrome17.08.02.014; 24.04.06.026; 18.06.01.0040.001269%Not Available
Medication residue present13.15.01.0320.016496%Not Available
Depersonalisation/derealisation disorder19.14.01.0040.001269%Not Available
Coeliac disease14.02.01.007; 07.17.01.008; 10.04.04.0120.002538%Not Available
Impulsive behaviour19.18.01.0010.001692%Not Available
Serum serotonin increased13.09.02.0010.000846%Not Available
The 11th Page    First    Pre   11    Total 11 Pages